Olanzapine vs Risperidone

How they're similar

Olanzapine and risperidone are both second-generation antipsychotics, sometimes called atypical antipsychotics. They share a lot at the mechanism level and in how they're used in practice.

• Both work by blocking dopamine D2 receptors and serotonin 5HT2A receptors in the brain. That combined action is what defines the atypical class and is the reason both drugs improve psychotic symptoms like hallucinations and delusions.
• Both are FDA-approved for schizophrenia and for acute mania in bipolar disorder. Both are also used for bipolar maintenance and for mixed episodes.
• Both come in oral tablet forms and both have long-acting injectable versions for people who benefit from a monthly or biweekly shot rather than daily pills.
• Both carry the class boxed warning about increased mortality when used in elderly patients with dementia-related psychosis, which is why neither is a first choice for behavioral symptoms of dementia.
• Both require metabolic monitoring. Standard practice is to check weight, blood pressure, and fasting glucose and lipids at baseline, again at three months, and then at least annually. Some clinicians check more often.
• Both can cause sedation, especially at higher doses and when starting out.
• Both can cause extrapyramidal symptoms, which are movement side effects that can include stiffness, tremor, restlessness, or slower movement. Risperidone causes these more often than olanzapine, but neither is free of them.
• Both are available as inexpensive generics.

The overlap means that in day-to-day use, the framework of monitoring, the way doses are titrated, and the pattern of counseling patients about what to watch for all look quite similar. The differences show up in which side effects come to the front and how quickly they do.

How they differ

The differences between olanzapine and risperidone are real and clinically meaningful. Olanzapine is heavier on the metabolic side. Risperidone is heavier on the prolactin and movement side. The table below summarizes the core points, and the paragraphs underneath fill in the practical detail.

Olanzapine carries the higher metabolic burden. Weight gain on olanzapine tends to be substantial, sometimes 10 to 20 pounds or more in the first year, and it can keep going. Along with weight, olanzapine raises triglycerides and cholesterol and increases the risk of developing type 2 diabetes, sometimes even without a big weight change. For a person who's already overweight, prediabetic, or has a strong family history of diabetes, that's a real consideration. Risperidone can also cause weight gain, but generally less than olanzapine, and the metabolic effects are usually milder.

Risperidone has the opposite pattern for prolactin. It raises prolactin more than any other drug in the atypical class, sometimes into ranges you'd otherwise see in a pituitary tumor. That elevation can cause a specific set of side effects: breast enlargement in men (gynecomastia), milk production not related to pregnancy (galactorrhea), missed or irregular periods in women, lowered sex drive, erectile problems, and long-term concerns about bone density. Not everyone develops these effects, and prolactin levels don't always predict symptoms, but the pattern is common enough that it's part of the standard counseling. Olanzapine also raises prolactin, but usually modestly and transiently.

Movement side effects, known as EPS, are more common with risperidone than with olanzapine, and the risk goes up as the risperidone dose climbs. Above about 4 mg a day, EPS becomes more likely. That includes akathisia, which is a specific kind of inner restlessness that patients often find distressing, as well as parkinsonian stiffness and slowed movement. Olanzapine can cause EPS too, but at usual doses it's less common. This difference matters when treating a patient who's especially sensitive to movement effects or who has any pre-existing movement disorder.

Sedation runs higher on olanzapine. Some patients find that helpful, especially early on when insomnia or agitation is part of the picture. Others find it hard to work through, and it can persist. Risperidone is less sedating overall, though it isn't stimulating either.

Risperidone has one approval that olanzapine doesn't share: it's approved by the FDA for irritability associated with autism in children and adolescents. That specific approval, along with a body of pediatric data, makes risperidone a common choice when treating severe irritability, aggression, or self-injurious behavior in kids on the autism spectrum. Aripiprazole shares that approval, but olanzapine does not.

Both drugs have long-acting injectable versions, which can be useful for people who struggle with daily adherence or who prefer not to think about pills every day. Olanzapine has Zyprexa Relprevv, given every two to four weeks, though it requires monitoring for a rare post-injection sedation reaction. Risperidone has several long-acting forms including biweekly, monthly, and even weekly options depending on which product is used.

Side effect tendencies

The two drugs share a general side effect list but differ in emphasis. Both can cause sedation, dry mouth, constipation, dizziness, and sexual side effects. Both can cause increased appetite. Where they diverge is in which of those effects tend to be the biggest problem for a given patient.

On olanzapine, the effect that patients notice first and that clinicians worry about most is weight gain. Appetite often increases within the first weeks. Cravings, especially for carbohydrates, are common. Weight tends to climb steadily for the first several months, and while it usually plateaus, it often doesn't reverse without significant effort. Along with weight, olanzapine can cause fatigue, sedation that lingers into the day, and increases in blood sugar and lipids that show up on lab work even before the patient feels different.

On risperidone, the effects patients tend to notice first are movement-related and hormonal. Some patients feel a restless, can't-sit-still feeling within the first days or weeks of starting or increasing the dose. That's akathisia, and it can be mistaken for worsening anxiety or agitation. The hormonal effects from prolactin elevation, including breast changes, galactorrhea, menstrual irregularities, and sexual side effects, can take weeks to months to show up but often persist as long as the medication is continued. Risperidone can also cause orthostatic hypotension during titration, so slow dose increases are important.

Both drugs can cause dyskinesias, including tardive dyskinesia, which is a movement disorder that can become permanent. Risperidone's higher EPS burden makes this slightly more of a concern, but neither drug is free of the risk, and monitoring for abnormal movements is part of routine care with any antipsychotic.

What tips the choice

Because these two drugs work about equally well for most cases of schizophrenia and bipolar mania, the choice usually turns on what a specific patient can afford to tolerate.

A clinician might choose olanzapine when the patient is thin, has no metabolic concerns, and either needs the sedation as part of treatment or won't be bothered by it. Olanzapine is often used in acute inpatient settings where sedation is useful and where rapid symptom control matters. It's also a common choice for someone who's already had EPS or prolactin problems on another antipsychotic and needs something with a lower risk of both. Prior response also weighs in. If someone has done well on olanzapine before, that's usually the drug to return to.

A clinician might choose risperidone when metabolic burden is a real concern, when there's family history of diabetes, or when the patient is already overweight and wants to avoid making that worse. Risperidone is also a natural first pick for a child or adolescent with autism-related irritability, because of the specific approval and the pediatric evidence base. It's a common choice in early psychosis programs and in outpatient settings where simple oral dosing and once or twice daily administration are practical.

Age and metabolic risk factor in strongly. A 22-year-old with a first episode of psychosis and no metabolic problems has more room to tolerate olanzapine, though many clinicians still avoid it as a first choice because of the weight burden over years of treatment. A 50-year-old with prediabetes and a family history of type 2 diabetes might be steered toward risperidone or a different agent entirely.

Cost and access are similar. Both are inexpensive generics, and both are widely available. Long-acting injectable options exist for both, so if that's part of the treatment plan, neither drug forces a specific route.

Some patients simply prefer one side effect profile over another. Someone who values energy and cognitive sharpness might prefer risperidone's less sedating profile. Someone whose main complaint is insomnia or agitation might tolerate olanzapine's sedation better. These are conversations worth having openly with a prescriber, because tolerability drives adherence, and adherence drives outcomes.

Common questions

Which one causes more weight gain? Olanzapine causes more weight gain than risperidone on average, and it's often the biggest concern with olanzapine treatment. Weight gain of 10 to 20 pounds or more in the first year isn't unusual. Risperidone can cause weight gain too, but generally less. If weight is a specific concern, that usually shifts the choice toward risperidone or an even more weight-neutral option like aripiprazole. Regular weight checks, activity, and dietary support all help but don't fully offset the drug effect.

What are the prolactin side effects, and how common are they on risperidone? Prolactin is a hormone that normally rises during pregnancy and breastfeeding. When an antipsychotic raises it outside of that context, it can cause breast enlargement in men, milk production in men or women who aren't pregnant, missed periods, lowered sex drive, and erectile problems. Long-term prolactin elevation can also affect bone density. Risperidone raises prolactin more than any other antipsychotic in current use, and these effects are common enough that they're part of routine counseling. Not every patient has symptoms even when prolactin lab values are high, but if symptoms appear, that's a reason to talk to a prescriber about a dose reduction or a switch.

Can I switch between them? Yes, and it's common. A prescriber can cross-taper, lowering one drug while introducing the other, or make a more direct switch depending on the situation. Switching is often done because of specific side effect problems, like weight gain on olanzapine or prolactin symptoms on risperidone. It should always be planned with a prescriber, because stopping antipsychotics abruptly can cause withdrawal symptoms and, more importantly, can allow the underlying illness to return.

Are the long-acting shots equally good? The oral and long-acting injectable versions of each drug work through the same mechanism, but the injectables provide steadier drug levels and remove the need for daily pills. They're often used for people who've had trouble with adherence or who prefer not to think about medication every day. Olanzapine's injectable requires monitoring after each dose for a rare sedation reaction, which limits where it can be given. Risperidone has several LAI options with different dosing intervals, which gives more flexibility. Whether an LAI is right depends on the person, not the drug itself.

Do I need blood work while taking these? Yes. Both drugs require metabolic monitoring. Standard practice is to check weight and blood pressure at every visit, and to check fasting glucose and a lipid panel at baseline, at three months, and then at least once a year. Some clinicians also check prolactin, especially on risperidone if there are symptoms. If any of these labs move in the wrong direction, that's a conversation about diet, activity, other medications to help, or possibly a switch.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Olanzapine (Zyprexa) prescribing information.
2. U.S. Food and Drug Administration. Risperidone (Risperdal) prescribing information.
3. MedlinePlus, U.S. National Library of Medicine.
4. National Institute of Mental Health. Mental health medications.